1. Home
  2. CGNT vs OABI Comparison

CGNT vs OABI Comparison

Compare CGNT & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CGNT

Cognyte Software Ltd.

HOLD

Current Price

$8.08

Market Cap

679.9M

Sector

Technology

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$3.95

Market Cap

294.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CGNT
OABI
Founded
2020
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
679.9M
294.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CGNT
OABI
Price
$8.08
$3.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$13.50
$4.50
AVG Volume (30 Days)
605.7K
2.1M
Earning Date
06-10-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.56
EPS
N/A
N/A
Revenue
N/A
$18,666,000.00
Revenue This Year
$13.73
$52.42
Revenue Next Year
$10.45
$64.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.29
$1.32
52 Week High
$12.31
$5.43

Technical Indicators

Market Signals
Indicator
CGNT
OABI
Relative Strength Index (RSI) 35.58 51.56
Support Level $7.87 $1.71
Resistance Level $9.33 $5.43
Average True Range (ATR) 0.34 0.33
MACD -0.06 -0.13
Stochastic Oscillator 11.61 4.28

Price Performance

Historical Comparison
CGNT
OABI

About CGNT Cognyte Software Ltd.

Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: